BioXcel Therapeutics, Inc. (BTAI)
NASDAQ: BTAI · IEX Real-Time Price · USD
18.31
+0.16 (0.88%)
Jun 2, 2023, 11:47 AM EDT - Market open
Income Statement (Annual)
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Year | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.38 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0.02 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0.36 | 0 | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 68.76 | 54.23 | 24.3 | 7.8 | 5.4 | 1.85 | 0.72 |
| Research & Development | 91.24 | 52.71 | 58 | 25.8 | 14.56 | 2.69 | 1.4 |
| Operating Expenses | 160 | 106.94 | 82.3 | 33.6 | 19.96 | 4.54 | 2.12 |
| Operating Income | -159.65 | -106.94 | -82.3 | -33.6 | -19.96 | -4.54 | -2.12 |
| Interest Expense / Income | 8.21 | 0.04 | 0.03 | 0.02 | 0 | 0 | 0 |
| Other Expense / Income | -2.1 | -0.04 | -0.16 | -0.65 | -0.69 | 0 | - |
| Pretax Income | -165.76 | -106.93 | -82.17 | -32.97 | -19.27 | -4.54 | -2.12 |
| Net Income | -165.76 | -106.93 | -82.17 | -32.97 | -19.27 | -4.54 | -2.12 |
| Shares Outstanding (Basic) | 28 | 26 | 22 | 16 | 15 | 10 | 9 |
| Shares Outstanding (Diluted) | 28 | 26 | 22 | 16 | 15 | 10 | 9 |
| Shares Change | 6.23% | 21.63% | 33.11% | 11.79% | 50.45% | 2.16% | - |
| EPS (Basic) | -5.92 | -4.05 | -3.79 | -2.02 | -1.32 | -0.47 | -0.22 |
| EPS (Diluted) | -5.92 | -4.05 | -3.79 | -2.02 | -1.32 | -0.47 | -0.22 |
| Free Cash Flow Per Share | -4.84 | -3.13 | -3.08 | -1.72 | -0.95 | -0.23 | -0.14 |
| Gross Margin | 94.67% | - | - | - | - | - | - |
| Operating Margin | -42572.00% | - | - | - | - | - | - |
| Profit Margin | -44201.87% | - | - | - | - | - | - |
| Free Cash Flow Margin | -36128.00% | - | - | - | - | - | - |
| EBITDA | -157.22 | -106.59 | -81.95 | -32.79 | -19.25 | -4.54 | -2.12 |
| EBITDA Margin | -41924.53% | - | - | - | - | - | - |
| Depreciation & Amortization | 0.33 | 0.3 | 0.19 | 0.16 | 0.02 | 0 | 0 |
| EBIT | -157.54 | -106.89 | -82.14 | -32.95 | -19.27 | -4.54 | -2.12 |
| EBIT Margin | -42011.73% | - | - | - | - | - | - |
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).